Research - In investing and trading, understanding where expectations stand for a company or equity is half the battle. In the case of large, profitable listed companies, that’s often earnings expectations: a beat is only a beat because it topped market expectations. In the case of bio/pharma stocks, we make the same evaluations for binary events, like mid-stage study results.
Read nowInsights - Titan Pharmaceuticals’ (TTNP) implantable device for the treatment of opioid addiction performed as well as standard sublingual buprenorphine tablets in a phase 3 study, the … Continue Reading
Read nowInsights - Titan Pharmaceuticals (TTNP) announced on Tuesday that enrollment in a final phase 3 trial of Probuphine has reached the halfway mark, and that the company continues … Continue Reading
Read nowRecap - Happy holidays from the PropThink editorial team! We hope you’re enjoying time with friends and family as we wrap up another busy holiday season and … Continue Reading
Read nowLong Ideas - BioDelivery Sciences (BDSI) on Monday entered into a $20 million senior secured loan with MidCap Financial and issued to the group a warrant to purchase … Continue Reading
Read nowLong Ideas - Cell therapy developers Athersys and Cytomedix target the immense stroke treatment market. Mr. Napodano laid out the theses for these two stem cell developers, although … Continue Reading
Read nowLong Ideas - This week was dominated by a number of binary events (which we outlined on Monday), two of which played out against us; Dr. Chaudhry expected that … Continue Reading
Read now
